Table II.
Immunohistochemical staining of 17 breast cancer biopsies.
| Sample | CD68 | CD163 | ERα (%) | ERβ1 (%) | PR (%) | HER-2 | Ki-67 (%) | MMP-9 (T/S) | uPAR (T/S) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3 | 3 | 90 | 100 | 0 | 3+ | 15 | 3 | 3 | 2 | 0 |
| 2 | 1 | 1 | 100 | 95 | 100 | 2+ | 0 | 3 | 3 | 0 | 0 |
| 3 | 2 | 2 | 75 | 30 | 75 | 0 | 25 | 3 | 2 | 1 | 0 |
| 4 | 3 | 3 | 0 | 95 | 0 | 3+ | 50 | 3 | 3 | 1 | 0 |
| 5 | 2 | 2 | 0 | 70 | 0 | 3+ | 25 | 3 | 3 | 0 | 0 |
| 6 | 1 | 1 | 80 | 95 | 5 | 1+ | 5 | 3 | 3 | 0 | 0 |
| 7 | 2 | 2 | 30 | 60 | 10 | 3+ | 8 | 3 | 2 | 0 | 0 |
| 8 | 1 | 1 | 80 | 60 | 90 | 0 | 5 | 3 | 2 | 0 | 0 |
| 9 | 1 | 2 | 90 | 95 | 1 | 0 | 8 | 3 | 3 | 1 | 0 |
| 10 | 3 | 3 | 0 | 90 | 0 | 0 | 70 | 3 | 3 | 3 | 3 |
| 11 | 3 | 3 | 1 | 90 | 1 | 2+ | 50 | 3 | 2 | 2 | 0 |
| 12 | 3 | 3 | 0 | 95 | 0 | 3+ | 25 | 3 | NA | 1 | NA |
| 13 | 2 | 1 | 40 | 60 | 0 | 2+ | 10 | 3 | 2 | NA | NA |
| 14 | 2 | 2 | 60 | 80 | 70 | 1+ | 45 | 3 | 2 | 3 | 2 |
| 15 | 3 | 3 | 1 | 80 | 4 | 1+ | 15 | 3 | 3 | 2 | 0 |
| 16 | 3 | 3 | 0 | 50 | 0 | 2+ | 17 | 3 | 3 | NA | NA |
| 17 | 2 | 2 | 90 | 50 | 100 | 0 | 15 | 3 | 1 | 1 | 0 |
HER-2, human epidermal growth factor 2; MMP-9, matrix metalloproteinase-9; uPAR, urokinase-type plasminogen activator receptor; ERα, estrogen receptor α; ERβ1, estrogen receptor β1; PR, progesterone receptor. T, positive tumor cells; S, positive macrophage-like stroma cells; NA, not available.